This inventor holds 4 USPTO granted patents and 3 published patent applications. Top assignee: Crescendo Biologics Limited. Active years: 2022-2024.
Company Filing History:
Years Active: 2022-2024
Title: Christine Rossant: Innovator in Antibody Development
Introduction
Christine Rossant is a prominent inventor based in Cambridge, GB. She has made significant contributions to the field of biotechnology, particularly in the development of innovative antibody therapies. With a total of four patents to her name, Rossant is recognized for her groundbreaking work in the treatment and detection of diseases.
Latest Patents
Among her latest patents, Rossant has developed single domain antibodies that bind to CD137. This invention relates to CD137 binding agents and their use in the treatment, prevention, and detection of various diseases. Another notable patent involves single domain antibodies to programmed cell death (PD-1). This invention focuses on PD-1 binding agents that do not block the interaction of PD-1 with its ligands, providing new avenues for treatment, prevention, and detection of diseases.
Career Highlights
Christine Rossant is currently associated with Crescendo Biologics Limited, where she continues to advance her research and development efforts. Her work has positioned her as a key figure in the biotechnology sector, contributing to the understanding and application of antibody therapies.
Collaborations
Rossant collaborates with esteemed colleagues, including James Legg and Yumin Teng, who share her vision for innovative solutions in biotechnology. Their combined expertise enhances the potential for groundbreaking discoveries in the field.
Conclusion
Christine Rossant's contributions to antibody development exemplify her commitment to advancing medical science. Her innovative patents and collaborations highlight her role as a leading inventor in the biotechnology industry.